BRIEF published on 09/03/2026 at 19:20, 21 days 10 hours ago Change at the helm of Poxel: Laure-Hélène Mercier appointed President Shareholders Biotechnology Governance Appointment Poxel
BRIEF published on 09/03/2026 at 19:20, 21 days 10 hours ago Laure-Hélène Mercier Appointed Chair of Poxel's Board Biotechnology Corporate Governance Board Appointment Poxel Financial Oversight
PRESS RELEASE published on 09/03/2026 at 19:15, 21 days 10 hours ago Inside Information / Other news releases Laure-Hélène Mercier appointed as Chair of Poxel's Board of Directors, enhancing governance and financial oversight. Sophie Jacq Lapointe steps down with gratitude. Poxel focuses on metabolic diseases and HCM treatments Governance Metabolic Diseases Poxel Laure-Hélène Mercier HCM
BRIEF published on 07/30/2026 at 21:35, 1 month 25 days ago Poxel Records Positive Turnover amidst Financial Statement Postponement Financial Statements Royalties Poxel TWYMEEG® Sales Debt Valuation
BRIEF published on 07/30/2026 at 21:35, 1 month 25 days ago Poxel: Q2 2026 Results and 2025 Financial Statements Report Revenue TWYMEEG® Poxel Sumitomo Pharma 2025 Accounts
PRESS RELEASE published on 07/30/2026 at 21:30, 1 month 25 days ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 3 months 14 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 3 months 14 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 3 months 14 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 5 months 24 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
Published on 09/25/2026 at 00:30, 5 hours 4 minutes ago Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 5 hours 19 minutes ago CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 7 hours 33 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 14 hours 39 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/25/2026 at 02:45, 2 hours 49 minutes ago Huagui Group: A Global Player Across Two RMB100-Billion Aquatic Markets, as Honghu Lotus Root Ranks No. 1 in Antioxidant Content
Published on 09/24/2026 at 20:29, 9 hours 5 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 10 hours 34 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 10 hours 53 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 11 hours 19 minutes ago Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:00, 11 hours 34 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 11 hours 34 minutes ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 11 hours 49 minutes ago Cegedim first-half 2026 results: profitability continues to improve
